TGA approves first non-hormonal menopause drug for hot flushes
Dr Karen Magraith says fezolinetant will most likely benefit women who cannot use menopausal hormone therapy.
GPs can now prescribe the non-hormonal menopause drug fezolinetant to women with moderate to severe vasomotor symptoms, following TGA approval of the first-of-its-kind treatment.
The once-daily pill contains 45mg fezolinetant (Veoza), which is a selective neurokinin-3 receptor agonist that acts on the thermoregulatory centre in the hypothalamus.
Hobart GP Dr Karen Magraith said it was a welcome new option for treating menopause-related hot flushes and night sweats.
“This is the first type of medication that has been specifically designed for its effect on vasomotor symptoms rather than repurposing another drug and using it off label,” she told AusDoc.
